BlackRock Health Sciences Trust
NYSE:BMEBlackRock Health Sciences Trust is a closed-ended equity mutual fund launched by BlackRock, Inc. The fund is managed by BlackRock Advisors, LLC. It invests in the public equity markets of the United States. The fund seeks to invest in stocks of companies operating in the health sciences and related sectors, which include businesses involved in researching, developing, producing, distributing or delivering medical, dental, optical, pharmaceutical or biotechnology products, supplies, equipment, or services. It also invests through equity derivatives, with an emphasis on option writing. The fund benchmarks the performance of its portfolio against the Russell 3000 Healthcare Index. BlackRock Health Sciences Trust was formed on March 31, 2005 and is domiciled in the United States.
Plateau Energy Metals
CVE:PLUPlateau Energy Metals Inc., a junior resource company, engages in the acquisition, exploration, and evaluation of mineral properties in Peru. The company explores for lithium and uranium deposits. It holds interests in Falchani Lithium Project and Macusani Uranium Project in the Puno District of southeastern Peru. The company also holds a total of 151 mining concessions covering approximately 93,000 hectares on the Macusani Plateau in Peru. The company was formerly known as Plateau Uranium Inc. and changed its name to Plateau Energy Metals Inc. in March 2018. The company was founded in 2006 and is headquartered in Toronto, Canada.
Valeant Pharmaceuticals International
TSE:VRXValeant Pharmaceuticals International, Inc. operates as a multinational, specialty pharmaceutical, and medical device company that develops, manufactures, and markets a range of pharmaceuticals, over-the-counter (OTC) products, and medical devices. The company operates through three segments: Bausch + Lomb/International, Branded Rx, and U.S. Diversified Products. The Bausch + Lomb/International segment provides pharmaceutical products, OTC products, and medical device products, primarily consist of Bausch + Lomb products, with a focus on the vision care, surgical, consumer, and ophthalmology Rx products in the United States; and pharmaceutical products, generic pharmaceutical products, OTC products, medical device products, and Bausch + Lomb products in Canada, Europe, Asia, Australia and New Zealand, Latin America, Africa, and the Middle East. The Branded Rx segment sells gastrointestinal and dermatological products in the United States. The U.S. Diversified Products segment offers pharmaceutical products, OTC products, and medical device products in the areas of neurology and certain other therapeutic classes, including aesthetics. The company was founded in 1983 and is headquartered in Laval, Canada.